The absence of orexin results in narcolepsy-cataplexy. While the function of the central orexinergic system in sleep regulation has been well studied, the role of orexin in motor control is largely unknown. Here, we show that orexin-A acts via OX 1 and OX 2 receptors to directly depolarize neurons in the rat lateral vestibular nucleus (LVN), a subcortical motor center, and enhance their sensitivity. A dual ionic mechanism involving both Na + -Ca 2+ exchangers and inward rectifier K + channels underlies these effects. Furthermore, orexin-A regulates central vestibular-mediated posture, motor balance and negative geotaxis. Orexin is critical when an animal is facing a major motor challenge as opposed to during rest and general movements. Therefore, orexin participates not only in sleep and emotion (nonsomatic) but also in motor (somatic) regulation, suggesting that the central orexinergic system plays an important role in somatic-nonsomatic integration. These findings may account for why the absence of orexin results in narcolepsy-cataplexy.
INTRODUCTION
The last decade has witnessed significant advances in our understanding of the physiological roles of orexin (also known as hypocretin), a neuropeptide first identified in 1998 Sakurai et al., 1998) . As a neurotransmitter system originating uniquely from the lateral hypothalamus/perifornical area but projecting extensively to almost the whole brain (Broberger et al., 1998; Cutler et al., 1999; Peyron et al., 1998) , the central orexinergic system has been implicated in many basic nonsomatic functions, including the sleep/wake states, feeding, and reward processes (Kukkonen et al., 2002; Matsuki and Sakurai, 2008; Sakurai, 2007) . However, whether the central orexinergic system has a role in somatic motor control remains enigmatic.
Orexin knockout mice exhibit normal movement initiation and speed (Españ a et al., 2007) with only a slight decrease in motor activity compared with wild-type animals (Hara et al., 2001; Mieda et al., 2004; Mochizuki et al., 2004) . However, intriguingly, orexin deficiency in humans, dogs, and rodents results in cataplexy, a motor deficit characterized by sudden loss of muscle tone (Chemelli et al., 1999; Sakurai, 2007) , highlighting the possibility of a modulatory role for orexin in motor control. But, since cataplexy is closely related to narcolepsy and often triggered by strong emotions, the effect of orexin on the motor system may be secondary to its actions on the neural circuits controlling sleep or emotions (Españ a et al., 2007; Hagan et al., 1999; Kiyashchenko et al., 2002; Matsuki and Sakurai, 2008) .
However, several lines of evidence indicate that the orexinergic system may directly participate in central motor control. First, numerous neuroanatomical and immunohistochemical studies reveal that essential subcortical motor structures, such as basal ganglia, cerebellum, and vestibular nuclei, receive direct innervation from the hypothalamic orexinergic neurons (Cutler et al., 1999; Peyron et al., 1998) . Second, during movements, orexinergic neurons are particularly active (Estabrooke et al., 2001; Lee et al., 2005; Mileykovskiy et al., 2005; Torterolo et al., 2003) and orexin release increases (Kiyashchenko et al., 2002; Martins et al., 2004; Wu et al., 2002) . Finally, injection of orexin into the midbrain locomotor region of decerebrate cats triggers locomotion and facilitates muscle tone (Takakusaki et al., 2005) . Thus, the role of central orexinergic system in motor control needs to be clarified.
In the present study, to reveal the exact relationship between the central orexinergic system and motor control, the effects of orexin on the motor system and the underlying mechanisms were investigated at molecular, cellular, and behavioral levels. Considering that cataplexy induced by orexin deficiency is characterized by sudden loss of muscle tone and the central vestibular system plays a critical role in control of muscle tone and postural control (Angelaki and Cullen, 2008; Barmack, 2003) , we focused on the effects of orexin on the vestibular nuclear complex in the brainstem. Moreover, compared to other sensorimotor circuits, the central vestibular circuitry exhibits a linear input-output transformation which is closely linked to vestibular reflexes (Bagnall et al., 2008) . This distinctive feature enables any modulation on the vestibular nuclei, including orexinergic, to be linearly transduced into the final output of the vestibular circuitry and reflected in motor behavior. Therefore, this study, we concentrated on the lateral vestibular nucleus (LVN, or Deiters' nucleus) in the vestibular nuclear complex, a nucleus that directly contributes to adjustment of muscle tone for both postural maintenance and the alternative change from the extensor to the flexor phase during locomotion (Molina-Negro et al., 1980; Wilson and Peterson, 1978) . Carrying out quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence techniques, we first investigated expression and distribution of orexin receptors in the LVN in rats. Next, we examined in brain slices the electrophysiological effects of orexin on the LVN neurons using whole-cell patchclamp recordings. Finally, we determined whether orexin regulates vestibular-mediated motor behaviors. The results demonstrate that orexin activates LVN neurons and promotes vestibular-mediated motor behaviors, implicating orexin and the central orexinergic system in the direct control of somatic motor behavior.
RESULTS

Both OX 1 and OX 2 Receptors Are Expressed in the LVN and Localized in Giant Neurons
We assessed the expression of OX 1 and OX 2 receptor mRNAs in rat LVN by quantitative real-time RT-PCR. The rat LVN tissues, localized between À10.50 and À11.30 mm from bregma ( Figures  1A and 1B) , were extracted according to the rat brain atlas of Paxinos and Watson (2007) . Amplification and melting temperature curves of ox-r1 and ox-r2 (genes of OX 1 and OX 2 receptors) and gapdh (the control housekeeping gene) show the cycle thresholds (C t ) for all genes ( Figure 1C ) and demonstrate that only one product per gene was generated ( Figure 1D ). As shown in Figure 1E , both OX 1 and OX 2 receptor mRNAs were detected in the rat LVN.
To map the distribution of orexin receptors, we performed immunostaining of the rat brain slices containing the LVN with an antibody against OX 1 and OX 2 receptors, respectively. We found that both OX 1 and OX 2 receptors were localized in the LVN ( Figures 1F1, 1F2 , 1G1, and 1G2) and present in all the large neurons (diameter >35 mm) ( Figures 1F3 and 1G3 ). These large neurons are giant Deiters' neurons (Shamboul, 1979; Suá rez et al., 1993) , whose axons form an important part of the posterior longitudinal bundle that controls the vestibulospinal reflexes.
Orexin-A Excites LVN Neurons by Activation of Both OX 1 and OX 2 Receptors Given the finding of the expression and localization of the orexin receptors in the LVN and considering previous reports of moderately dense orexinergic innervation of the vestibular nuclei in rats (Cutler et al., 1999; Peyron et al., 1998) , we carried out voltageclamp recordings in the giant LVN neurons (diameter >35 mm) to examine the effect of orexin on whole-cell currents of LVN neurons and the underlying mechanisms by using brain slice preparations (see also Figure 1B ). In total, we recorded 69 LVN neurons with the membrane resistance higher than 150 MU. As (Paxinos and Watson, 2007) , localizing the LVN between À10.30 and À11.60 mm from the bregma. LVN tissue punches for analysis of expression of ox-r1 and ox-r2 were collected from brain slices obtained using these coordinates. (B) Diagram of coronal brainstem sections from rostral to caudal levels shows the area of the LVN investigated in this RT-PCR as well as the following electrophysiological studies. (C) Amplification curves for ox-r1 (red), ox-r2 (blue), and gapdh (black) were obtained to identify the cycle thresholds (C t ) at which reporter fluorescence intensity significantly exceeded background fluorescence signals. (D) A melting temperature curve analysis was performed to determine that the reactions yielded only one product per gene. Each peak corresponds to the melting temperature of ox-r1 (red), ox-r2 (blue), or gapdh (black). (E) Bar graphs showing relative expression of ox-r1 and ox-r2 in LVN. (F1-F3) Antibody staining for OX 1 receptors in the rat LVN.
(G1-G3) Antibody staining for OX 2 receptors in the rat LVN. Note that both OX 1 and OX 2 receptor immunostainings particularly enriched in the large-size LVN neurons (diameter > 35 mm). (H1-H3) Negative staining control by omitting the primary antiserum. Scale bars: (F1), (G1), and (H1), 750 mm; (F2), (G2), and (H2), 195 mm; (F3), (G3), and (H3), 23 mm. 4V, 4th ventricle; g7, genu of the facial nerve; icp, inferior cerebellar peduncle; LVN, lateral vestibular nucleus; sp5, spinal trigeminal tract. all of these cells had a diameter >35 mm and a whole-cell membrane capacitance >150 pF, we conclude that the neurons studied were giant Deiters' neurons (Uno et al., 2003; Zhang et al., 2008) .
Orexins have two splice variants, orexin-A and orexin-B, that are derived from a common pre-pro-orexin gene (Kukkonen et al., 2002; Sakurai, 2007) . Both orexin-A and orexin-B act on two G protein-coupled receptors, OX 1 and OX 2 receptors (Kukkonen et al., 2002; Sakurai, 2007) . We found that brief application (1 min) of orexin-A (10-300 nM) elicited a significant inward whole-cell current on a majority of the recorded LVN neurons (63/69, 91.3%). For the remaining six neurons, orexin-A induced an outward current (3/69, 4.3%) or had no effect (3/69, 4.3%). The orexin-A-induced excitation on LVN neurons was concentration-dependent ( Figures 2A1 and 2A2 ). Application of 30, 50, 100 nM orexin-A elicited an inward current of -38.4 ± 5.9 pA (n = 8), -53.4 ± 9.6 pA (n = 7), -73.8 ± 13.0 pA (n = 7), respectively. Fitting the concentration-response curve from 14 LVN neurons yielded that the mean concentration of orexin-A for half-maximal activation (EC 50 ) was 59.0 ± 17.9 nM. Additionally, the effect of orexin-B on the LVN neurons (n = 6) was similar to that of orexin-A ( Figure 2B ).
We ]-orexin-B elicited a concentration-dependent inward current of -26.5 ± 2.2 pA and -71.6 ± 6.6 pA, respectively, suggesting that OX 2 receptors are involved in the action of orexin on the LVN neurons. In addition, on the same six LVN neurons, the orexin-A-elicited inward currents were partly blocked by SB334867. After application of 10 mM SB334867, 30 nM orexin-A-elicited currents decreased from -43.4 ± 6.2 pA to -22.2 ± 2.9 pA (p < 0.01). Together, these results provide direct electrophysiological evidence that orexin excites the LVN neurons by activation of both OX 1 and OX 2 receptors, consistent with our molecular and immunostaining results.
Orexin-A Excites the LVN Neurons via a Dual Ionic Mechanism
To clarify the ionic basis underlying the orexin-induced excitation, first we determined whether the action of orexin-A on the LVN neurons was a direct postsynaptic effect. The fact that application of orexin-A onto LVN neurons evokes a stable inward current instead of EPSC/IPSCs suggests a direct postsynaptic excitatory effect. We also used 0.3 mM TTX for confirmation. As shown in Figures 3A and 3B1 , TTX did not block the 100 nM orexin-A-elicited inward currents (i.e., -71.8 ± 10.7 pA and -69.4 ± 9.4 pA before and after applying TTX, p = 0.212; n = 5), strongly suggesting that the excitation of orexin on the LVN neurons is a direct postsynaptic action. Furthermore, GABA A receptor (100 mM picrotoxin) and ionotropic glutamate receptor (1 mM kynurenate) antagonists still did not influence the orexin-elicited inward current (i.e., -72.3 ± 22.0 pA and -73.5 ± 25.3 pA before and after application, p = 0.811; n = 4; see Figure S1 available online), confirming the direct postsynaptic mechanism. Moreover, accompanying the orexin-Ainduced inward currents, the input conductance of the cells slightly decreased (76.4% ± 6.3% of the control; Figures 3A  and 3B2 ), and the change of conductance was not blocked by TTX (77.4% ± 5.9% of the control, p = 0.234; Figures 3A and  3B2 ), suggesting that orexin-A caused a closure of ion channels on the postsynaptic membrane. Next, we determined the I-V curves in response to orexin-A to investigate the underlying ionic mechanism. We employed slow ramp command tests (dV/dt = -10 mV/s, ranged from -65 mV to -120 mV) to evaluate the I-V curves for a large voltage range in the absence and presence of orexin-A. We observed four types of orexin-A-induced changes on the I-V curves from 18 LVN neurons. Among 55.6% (10/18) of these neurons, the orexin-Aelicited inward current was smaller at the more hyperpolarized potential of -120 mV as compared with -65 mV ( Figure 3C1 ), and in 22.2% (4/18) of neurons, the orexin-A-induced inward current had a larger amplitude at -120 mV as compared with -65 mV ( Figure 3C2 ). In 16.7% (3/18) of the neurons tested, orexin-A elicited an inward current that reversed near the calculated E k of -105 mV ( Figure 3C3 ), suggesting the involvement of K + channels. In the remaining 1 neuron, the orexin-A-elicited inward current was similar in amplitude at -65 and -120 mV, although its amplitude first decreased then increased along with the hyperpolarization ( Figure 3C4 ). The diversity of the changes in the I-V curves implies that more than one ionic mechanism is involved in the orexin-induced excitation on the LVN neurons, in which K + may be an important component.
Blockage of K + channels, activation of nonselective cation channels and/or electrogenic Na + -Ca 2+ exchangers have been reported to mediate the orexin-A-elicited inward current (Eriksson et al., 2001; Liu et al., 2002; Wu et al., 2004) . Notably, decrease of input conductance (see Figures 3A and 3B2 ) and the reversal potential near the calculated E k (see Figure 3C3 ) together indicate that orexin-A suppressed K + channels to excite LVN neurons. Furthermore, we assessed other ionic mechanism (s) underlying the excitatory effects of orexin on LVN neurons. We applied a selective blocker of Na + -Ca 2+ exchangers (50 mM KB-R7943) on 6 LVN neurons and observed a partial inhibition of the orexin-A-elicited inward current (49.0% ± 5.4% of the control) ( Figures 4A and 4D ), suggesting an activation of electrogenic Na + -Ca 2+ exchangers. Then, under a condition of blockage of Na + -Ca 2+ exchangers by continuously perfusing the slice with KB-R7943, we used slow ramp command tests to obtain the I-V curves in the absence and presence of orexin-A (the left panel of Figure 4B1 ). Subtracting the control from the current recorded during orexin-A application yielded a difference current representing the orexin-A-induced current excluding the component of Na + -Ca 2+ exchangers (the right panel of Figure 4B1 ). The difference current obtained from the 6 LVN neurons ( Figure 4B2 ) exhibited two significant features: the difference current had a reversal potential of -100 mV that This I-V relationship change was observed in 55.6% (10/18) of these neurons tested, the orexin-A-induced inward current was smaller at the more hyperpolarized potential of -120 mV than at -65 mV. (C2) In 22.2% (4/18) of neurons, the orexin-A-induced inward current had a larger amplitude at -120 mV as compared with -65 mV. (C3) In 16.7% (3/18) of neurons, the orexin-A-induced inward current reversed near the calculated E k of -105 mV; C4, In the remaining one neuron, the orexin-A-elicited inward current was similar in amplitude at -65 and -120 mV, although its amplitude first decreased then increased along with the hyperpolarization. The diversity of the orexin-A-induced changes in I-V relationships suggests that more than one ionic basis is involved in orexin-A-elicited inward currents on LVN neurons.
Error bars represent SEM; n.s. indicates nonsignificant and *p < 0.05. See also Figure S1 .
was near the calculated E k and it was strongly outwardly rectifying. Considering orexin-A decreased input conductance, the result indicates that the K + channels blocked by orexin-A are the inward rectifier K + channels. To confirm these results, we applied Ba 2+ (1 mM), a blocker of K + channels, combined with 50 mM KB-R7943, on 5 LVN neurons. The orexin-A-elicited inward current was nearly totally blocked (10.5% ± 2.6% of the control) ( Figures 4C and 4D ), suggesting that orexin-A excites the LVN neurons via a dual ionic mechanism, including both activation of Na + -Ca 2+ exchangers and closure of inward rectifier K + channels. Other two specific blockers for Na + -Ca 2+ exchangers (10 mM SN-6) and inward rectifier K + channels (100 nM tertiapin-Q) further confirmed the dual ionic mechanism ( Figure S2 ).
Orexin-A Directly Increases Activities and Sensitivities of LVN Neurons
Given that orexin-A induces an inward current on the LVN neurons, we carried out current clamp experiments to address whether orexin-A directly activates LVN neurons. The LVN contains two classes of neurons, one that has spontaneous discharge and the other (30%-50% of neurons) that has no spontaneous discharge (Uno et al., 2003; Zhang et al., 2008) . As expected, orexin-A (100 nM) elicited a significant increase in the discharge rates of 4 LVN spontaneous firing neurons ( Figure 5A ), and a sufficiently strong depolarization to activate firing in two silent neurons ( Figure 5B ). Plotting the interspike intervals (ISIs) and peristimulus time histograms (PSTHs) of the LVN neurons with spontaneous firing (Figures 5C and 5D) shows that, accompanied by a remarkable increase in the peak firing rates (146.9% ± 15.6% of the baseline of 6.8 ± 1.8 spikes/s), the spiking intervals were also significantly shortened by orexin-A. Therefore, orexin directly increases the firing of both spontaneous discharges and silent LVN neurons. Intriguingly, orexin-A also increased the sensitivity of the LVN neurons to a depolarizing ramp-like current stimulation (Figure 5E1 ), consisting of a 600 ms ramp (À150 pA to 150 pA, slope of 0.5 nA/s) followed by a long plateau of current (150 pA, 4400 ms) (Ris et al., 2001; Uno et al., 2003) . On 5 LVN neurons, orexin-A (100 nM) significantly shortened the first-spike latency from 449.3 ± 47.2 ms to 281.3 ± 35.4 ms (p < 0.05; Figure 5E2 ). Furthermore, orexin-A increased the rate of increase in the instantaneous firing rate ( Figure 5E3 ) of the LVN neurons from 29.2 ± 9.1 spikes/s/nA to 34.4 ± 9.4 spikes/s/nA (p < 0.01; Figure 5E4 ), consistent with an increase in the sensitivity of the cell to the current stimulation. However, orexin-A did not change (control, 1.70 ± 0.40 spikes/s; orexin-A, 1.53 ± 0.45 spikes/s, p = 0.132; Figure 5E5 ) the difference between the firing rate reached at the end of the ramp and the stable discharge rate reached at the end of the plateau (overshoot in spikes/s; Figure 5E3 ), i.e., orexin did not change the accommodation, which gives an indication of the unchanged dynamic properties of neurons by orexin. The increase in both the firing rate and sensitivity of LVN neurons suggests that the orexinergic afferent system in the LVN may have a potential physiological function on the vestibular-mediated motor behaviors. (B1) The I-V relationship of orexin-A-induced current in the ACSF containing KB-R7943. The difference current (orexin-A-induced current, right panel) was obtained by subtracting the control current from the current recorded during orexin-A application (left panel). (B2) Group data of the orexin-Ainduced currents on 6 tested LVN neurons. Note that in the presence of KB-R7943, the orexin-A-induced current showed an outward rectification and reversed at the potential of À100 mV, which was near the calculated E k , indicating orexin blocked the inward rectifier K + channels.
(C) KB-R7943 and Ba
2+
, a blocker of K + channels, totally blocked orexin-Ainduced inward current on a LVN neuron, suggesting the orexin-A excited the LVN neurons via a dual ionic mechanism including both activation of Na + -Ca 2+ exchangers and closure of inward rectifier K + channels.
(D) The effects of KB-R7943 and Ba 2+ on orexin-A-induced inward current in tested LVN neurons were summarized. Error bars represent SEM; **p < 0.01. See also Figure S2 .
Orexin-A Excites LVN Neurons In Vivo and Improves Vestibular-Related Motor Behaviors
We microinjected orexin-A (10 mM, 1 ml) into the LVN and used extracellular recording to observe its actions in vivo in urethane-anesthetized rats. To estimate the effective extent of diffusion of the injected compounds in the LVN, units from 0.5-2.0 mm away from the injection sites were recorded (Song et al., 2006) . Orexin-A significantly excited 6 of 8 recorded LVN neurons (75%) that were close (0.5-1.3 mm) to the injection site while vehicle (1 ml) had no effect (n = 6) ( Figure 6A2 ), suggesting that orexin endogenously released from afferent fibers may directly regulate the firing of LVN neurons. The mean latency of the orexin-induced excitatory effects on LVN neurons in vivo was 95 ± 6 s (ranged from 78 to 115 s), whereas the mean duration was 681 ± 303 s (ranged from 150 to 1310 s). There was a negative correlation between the duration and latency of the orexin-induced excitatory responses on LVN neurons (linear regression, r = À0.980), implicating a spread of microinjected orexin in the LVN. Microinjection of orexin-A (n = 8) and vehicle (n = 8) did not induce neurons near the inner edge of the LVN (1.5-2.0 mm away from the injection site) any changes in discharge frequency (Figures 6A1 and 6A3) , indicating the present microinjections, which were also applied in the following behavioral studies, only activated neurons strictly located in the LVN. Representative coronal histological sections from the rat brain showing two injection sites in the superficial LVN, the tracts of the guide tubes above the bilateral nuclei, and the reconstructed microinjection sites within the LVN (n = 174 in each side) are presented in Figures 6B and 6C , respectively.
Because of the key position of the LVN in the vestibulospinal reflexes and posture control, we asked whether the excitatory effect of orexin on LVN neurons influences vestibular-mediated behaviors. Unilateral microinjection of orexin-A (10 mM, 1 ml) into the rat LVN induced an obvious postural syndrome showing a tilt of head and body to the contralateral side with extension of the ipsilateral limbs, consistent with increased firing of the ipsilateral LVN. Furthermore, we counted the rotation numbers for 5 min by hanging the rat by its tail with its forepaws on the ground, and found that the rotations in the contralateral direction of the rats unilaterally microinjected with orexin-A (32.42 ± 2.63) were significantly increased (one-way ANOVA, F (2,33) = 112.47, p < 0.01) compared to those of the vehicle-treated group (4.33 ± 0.67) or the sham operated animals (4.83 ± 0.61) (Figure 6D) . The results strongly indicate that through directly exciting the LVN neurons, orexin may enhance the output of the LVN and consequently change body posture.
Next, since the LVN contributes not only static but also to dynamic postural changes during vestibulospinal reflexes (Molina-Negro et al., 1980; Wilson and Peterson, 1978) , we microinjected orexin-A (10 mM, 1 ml for each side) into the bilateral LVNs in rats to observe whether orexin influences motor behaviors in the horizontal balance beam and negative geotaxis tests. Both tests assess motor balance and coordination as well as vestibular function (Altman and Sudarshan, 1975; Hermans et al., 1992) . Orexin, rather than vehicle, immediately and significantly shortened the time that rats spent traversing the horizontal balance beam and the performance recovered in hours (repeated-measures two-way ANOVA: treatment, F (2,45) = 1.390, p = 0.260; time, F (3,135) = 9.139, p < 0.001; interaction, F (6,135) = 6.457, p < 0.001; Newman-Keuls post hoc testing revealed significant differences between the orexin-A injection group and sham or vehicle group at 0 hr after injection, p < 0.01; Figure 6E) . Moreover, in the negative geotaxis tests on a 40 incline, orexin reduced the time necessary to turn to 180 upward from an initial position with animals' heads facing downward and the performance also recovered in hours (repeated-measures two-way ANOVA, treatment, F (2,51) = 1.145, p = 0.326; time, F (3,153) = 4.877, p < 0.004; interaction, F (6,153) = 7.413, p < 0.001; Newman-Keuls post hoc testing indicated significant differences between the orexin-A injection group and sham or vehicle group at 0 hr after injection, p < 0.05 and 0.01, respectively; Figure 6F ). The improvement in vestibular-mediated balance and coordination suggests that orexin modulates neuronal activity and sensitivity of the LVN and contributes directly to vestibular-mediated motor and postural control.
Microinjection of SB334867 into the LVN Strongly Attenuates Rat Motor Performance during a Motor Challenge Rather Than General Movements
To further clarify how endogenous orexin modulates vestibularmediated motor and postural control, we microinjected SB334867 (5 mM, 1 ml), a selective OX 1 receptor antagonist, into the rat LVN bilaterally. Interestingly, SB334867 did not affect rat motor performance in either the horizontal balance beam (repeated-measures two-way ANOVA, treatment, F (2,27) = 0.066, p = 0.936; time, F (3,81) = 0.139, p = 0.937; interaction, F (6,81) = 0.563, p = 0.758) or negative geotaxis (repeated-measures two-way ANOVA, treatment, F (2,27) = 0.035, p = 0.966; time, F (3,81) = 1.022, p = 0.387; interaction, F (6,81) = 0.769, p = 0.596) (Figures 7A and 7B ). Nor did SB334867 elicit any inhibition of neuronal firing in the LVN (n = 7; Figures S3A and S3B) in the urethane-anesthetized rats, indicating that endogenous orexin may have no effect on the LVN under the conditions of resting or general movements.
Furthermore, considering that cataplexy induced by orexin deficiency is often triggered by a strong stimulus, we speculated that endogenous orexin may be critical for motor control when animals face a motor challenge rather than under rest conditions Error bars represent SEM; n.s. indicates nonsignificant; *p < 0.05 and **p < 0.01.
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Role for Orexin in Central Motor Control or general movements. Therefore, to test this hypothesis we used a modified inclined balance beam test at 40 as a greater motor challenge than horizontal balance beam and negative geotaxis. Consistent with the hypothesis, bilateral microinjection of SB334867 into the LVN immediately and significantly increased the time that rats spent traversing the inclined balance beam (repeated-measures two-way ANOVA, treatment, F (2,27) = 0.322, p = 0.728; time, F (3,81) = 44.418, p < 0.001; interaction, F (6,81) = 38.637, p < 0.001; Newman-Keuls post hoc testing indicated significant differences between SB334867 injection group and sham or vehicle group at 0 hr after injection, p < 0.05; Figure 7C ). The inhibitory effect of SB334867 on the motor behavior recovered in hours ( Figure 7C ).
To investigate another significant motor challenge, we employed an accelerating rota-rod test, used three different accelerations (0.12, 0.2, and 0.6 rpm/s). In test using an acceleration of 0.2 rpm/s, bilateral microinjection of SB334867 into the LVN immediately and significantly shortened the time that rats stayed on the accelerating rota-rod (repeated-measures two-way ANOVA, treatment, F (2,27) = 1.243, p = 0.304; time, F (3,81) = 11.562, p < 0.001; interaction, F (6,81) = 13.494, p < 0.001; Newman-Keuls post hoc testing indicated significant differences between SB334867 injection group and sham or vehicle group at 0 hr after injection, p < 0.01; Figure 7D ). The inhibitory effect of SB334867 on the motor behavior also recovered in hours ( Figure 7D ). In test using an acceleration of 0.12 or 0.6 rpm/s, there were the similar inhibitory effects of SB334867 ( Figures  S3C and S3D) . Moreover, intriguingly, the decrement of motor performance in accelerating rota-rod tests increased with the increase of the acceleration ( Figure 7E ), suggesting that the stronger the motor challenge faced by animals, the greater the degree of involvement of the central orexinergic system in motor control.
In addition, both spontaneous locomotor (one-way ANOVA, F (2,27) = 0.659, p = 0.525) and exploratory activity (one-way ANOVA, F (2,27) = 0.257, p = 0.775) in an open-field were not affected by microinjecting SB334867 into the bilateral LVNs (Figure 7F) . The results confirm that endogenous orexin is involved in the execution of challenging movements but not under resting conditions or for the execution of general movements. They also show that orexin acts through the LVN rather than as a secondary effect on arousal or emotion.
DISCUSSION
The occurrence of narcolepsy-cataplexy in the orexin knockout animals provides the most important clue for elucidating the relationship between the central orexinergic system and motor control (Chemelli et al., 1999; Sakurai, 2007) . However, the effects of orexin on sleep and/or emotion systems cannot be excluded. In the present study, we describe a role for the orexinergic system in central vestibular-mediated motor control. First, we found that both OX 1 and OX 2 receptors are expressed and localized in the LVN. Together with previous observations of orexinergic fibers in the vestibular nuclei (Cutler et al., 1999; Peyron et al., 1998) , these results confirm that there is an orexinergic innervation of the LVN. Second, in vitro and in vivo electrophysiological experiments demonstrate that orexin excites the LVN neurons through activation of both OX 1 and OX 2 receptors. Through a dual ionic mechanism, orexin increases the activity and the sensitivity of LVN neurons. Finally, we demonstrated significant orexin-induced postural changes and improvement in motor performances, with endogenous orexin playing a critical role in motor control when animals face a major motor challenge. These results provide strong evidence that the central orexinergic system is directly and actively involved in motor control.
Mechanism and Function of Orexin on LVN
Except for the suppression of glucose-responsive neurons in the ventromedial hypothalamic nucleus (Shiraishi et al., 2000) , orexin excites almost all target neurons in the central nervous system (Kukkonen et al., 2002; Sakurai, 2007) , including Deiters' neurons in the LVN. The ionic mechanisms for the action of orexin on these neurons include presynaptic effects (increased transmitter release via unknown mechanisms) and/or postsynaptic depolarization. The stable currents and lack of effect of TTX, picrotoxin, and kynurenate we observed in this study strongly suggest that the inward currents elicited by orexin in LVN neurons reflect direct postsynaptic excitation, although the effect of orexin on vestibular nerve inputs to LVN neurons in vivo is still unclear. It is well known that the postsynaptic signal transduction pathways coupled with OX 1 or OX 2 receptors are complex (Kukkonen et al., 2002; Matsuki and Sakurai, 2008; Sakurai, 2007) . In this study, we found that orexin excites LVN neurons by activation of both OX 1 or OX 2 receptors and a dual ionic mechanism including both activation of Na + -Ca 2+ exchangers and closure of inward rectifier K + channels. The actions of orexin on the activity and sensitivity of LVN neurons we observed reflect this dual ionic mechanism. Because the reversal potential of Na + -Ca 2+ exchangers is highly positive (Wu et al., 2004) , they are affected little by the fluctuation of membrane potential and their activation can provide an efficient force for depolarizing neurons. Thus, through activation of Na + -Ca 2+ exchangers orexin depolarizes LVN neurons, increasing the discharge of spontaneous firing neurons and evoking firing in silent neurons. In addition, inward rectifier K + channels that govern the resting membrane potential are shut off during depolarization and open to help repolarization (Hille, 2001; Nishida and MacKinnon, 2002) . Therefore, by closure of inward rectifier K + channels, orexin can not only increase firing rate but delay repolarization that consequently increases sensitivity of LVN neurons. On the other hand, orexin did not change the accommodation of instantaneous firing rate responded to the long plateau stimulus, suggesting that orexin does not influence the dynamic properties or basic response patterns of LVN neurons, as well as their basic function.
Notably, the activation of orexin on LVN neurons in vivo influences vestibular-mediated motor behaviors. Unilateral microinjection of orexin into the LVN elicits postural change, and bilateral microinjection of orexin promotes motor balance. These changes result from an enhanced output of LVN induced by orexin, since we observed an extending of ipsilateral forelimb and hindlimb following unilateral microinjection, which suggests an increase in muscle tone. The facilitation of muscle tone induced by the excitatory action of orexin on the LVN suggests that decreased orexinergic afferents on LVN may contribute to loss of muscle tone in cataplexy. Moreover, bilateral microinjection of orexin improves negative geotaxis, which is considered a general diagnostic of vestibular function and motor skills (Altman and Sudarshan, 1975; Hermans et al., 1992) . Since negative geotaxis is an automatic, stimulus-bound orientation movement and considering the linear property in input-output transduction of central vestibular nuclei (Bagnall et al., 2008) , we speculate that the orexin-induced increase of sensitivity of LVN neurons may enhance the responsiveness of the central vestibular circuitry to changes of direction and gravity, leading to an improvement in negative geotaxis. These behavioral results strongly suggest that the orexinergic afferents in the LVN may directly and actively modulate central vestibular-mediated motor behaviors.
Role of Orexin on Motor Control: Critical for Movements during Large Motor Challenges
Although previously there was no known involvement of orexin in the motor system except the cataplexy in orexin knockout animals (Kukkonen et al., 2002; Matsuki and Sakurai, 2008; Sakurai, 2007) , this study, together with several other recent reports, indicates a role of the central orexinergic system in motor control. In this and previous studies, we demonstrate an excitatory action of orexin on neurons in both the LVN and cerebellar nuclei (Yu et al., 2010) . Orexin also excites GABAergic neurons in the substantia nigra reticulata (Korotkova et al., 2002) and increases the activity and sensitivity of spinal motoneurons (Yamuy et al., 2004) , although their underlying mechanisms maybe different. The homogeneous excitatory effect of orexin on these neurons involved in motor control suggests that the central orexinergic system acts to uniformly and parallelly excite motor structures. Therefore, we speculate that this common excitation may help these motor structures maintain excitability at a certain level and also provide for an appropriate level of sensitivity for responding to inputs coding changes in internal and external environments. Via biasing neuronal activity and sensitivity in motor structures, the central orexinergic fibers may sequentially modulate motor behaviors.
However, an intriguing question is how endogenous orexin participates in central motor control. Although several studies reported that orexin neurons are especially active (Estabrooke et al., 2001; Lee et al., 2005; Mileykovskiy et al., 2005; Torterolo et al., 2003) and that orexin release increases during movements (Kiyashchenko et al., 2002; Martins et al., 2004; Wu et al., 2002) , interestingly, orexin knockout animals do not show apparent motor deficits except during cataplexy (Españ a et al., 2007) . In the present study, we suggest a specific position of the central orexinergic system in motor control. Our results demonstrate that endogenous orexin is critical for motor control for animals facing a major motor challenge. Therefore, the modulation of the central orexinergic system on motor control may be not readily noticeable when internal and external environments are relatively stable, as during rest or routine movements. During a significant behavioral challenge, the increased excitatory drive and sensitivity due to the release of orexin may be essential for ensuring prompt and appropriate magnitude motor responses. Moreover, the stronger the motor challenge faced by animals, the greater the degree of involvement of the central orexinergic system in motor control. Therefore, when encountering an unexpected challenge that requires a strong motor response, orexin deficiency results in cataplexy. Furthermore, given the recent finding that orexin promotes wakefulness by enhancing locomotion (Anaclet et al., 2009) , we suggest that narcolepsy-cataplexy caused by orexin deficiency may be, in part, a consequence of loss of orexinergic modulation on the motor system. Central Orexinergic System: A Potential Neural Substrate Responsible for Somatic-Nonsomatic Integration?
The central orexinergic system has been implicated in many nonsomatic basic functions, including sleep/wake states, energy homeostasis, neuroendocrine, and autonomic functions, and reward processes (Kukkonen et al., 2002; Matsuki and Sakurai, 2008; Sakurai, 2007) . In this study, we revealed that this system is directly involved in somatic motor control. Thus, through parallel modulation of both somatic and nonsomatic activities, the central orexinergic system may help to orchestrate an integrated and coordinated somatic-nonsomatic response that leads to the appropriate behavioral response to changes in the internal and external environment. Obviously, an intact behavior comprises both somatic and nonsomatic components and needs a somatic-nonsomatic integration involving various brain regions and discrete neuronal pathways (Zhu et al., 2006a) . Here, we speculate that the central orexinergic system is an important component of the neural substrates responsible for somatic-nonsomatic integration. We further suggest that narcolepsy-cataplexy caused by orexin deficiency is a simultaneous somatic and nonsomatic dysfunction in which somatic (motor) activities and some nonsomatic (sleep and emotional) responses are not correctly integrated and coordinated.
EXPERIMENTAL PROCEDURES Quantitative Real-Time RT-PCR and Immunofluorescence
Methods for quantitative real-time RT-PCR and immunofluorescence can be found in the Supplemental Information online. All experiments completely conformed to the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication 80-23, revised 1996) . All efforts were made to minimize the number of animals used and their suffering.
Electrophysiological Recordings
Coronal brainstem slices (300 mM in thickness) containing the LVN were prepared with a vibroslicer (VT 1200 S, Leica, Germany) from rats aged 12-16 days, according to the rat brain atlas (Paxinos and Watson, 2007) . The slices were incubated in artificial cerebrospinal fluid (ACSF, composition in mM: 124 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 1.3 MgSO 4 , 26 NaHCO 3 , 2 CaCl 2 and 10 D-glucose) equilibrated with 95% O 2 and 5% CO 2 at 35 C ± 0.5 C for at least 1 hour and then maintained at room temperature. During recording sessions, the slices were transferred to a submerged chamber and continuously superfused with 95% O 2 and 5% CO 2 oxygenated ACSF at a rate of 2 ml/min maintained at room temperature. Whole-cell recordings were performed on LVN neurons with borosilicate glass pipettes (3-5 MU) filled with an internal solution (composition in mM: 140 K-methylsulfate, 7 KCl, 2 MgCl 2 , 10 HEPES, 0.1 EGTA, 4 Na 2 -ATP, 0.4 GTP-Tris, adjusted to pH 7.25 with 1 M KOH). During recording sessions, LVN neurons were verified with an Olympus BX51WI microscope (Japan). Patch-clamp recordings were acquired with an Axopatch-200B amplifier (Axon Instruments, USA) and the signals were fed into a computer through a Digidata-1322A interface (Axon Instruments, USA) for data capture and analysis (pClamp 8.2, Axon Instruments, USA). Neurons were held at a membrane potential of -60 mV and characterized by injection of rectangular voltage pulse (5 mV, 50 ms) to monitor the whole-cell membrane capacitance, series resistance and membrane resistance. Neurons were excluded from the study if the series resistance was not stable or exceeded 20 MU.
We bathed the slices with orexin-A (10-300 nM, Tocris, UK) and orexin-B (100 nM, Tocris, UK) to stimulate the recorded neurons. [Ala 11 , ]-orexin-B (100-300 nM, Tocris, UK) and SB334867 (10 mM, Tocris, UK) were applied to assess the underlying receptor mechanism. TTX (0.3 mM, Alomone Labs, Israel), picrotoxin (100 mM, Tocris, UK) and kynurenate (1 mM, Tocris, UK) were used to confirm the postsynaptic effects of orexin. To assess the feature of orexin-induced whole cell current and the underlying ionic mechanism, in voltage-clamp recording, current-voltage plots (I-V curves) were obtained before and during drug application using a slow ramp command (dV/dt = -10 mV/s, ranged from -65 mV to -120 mV) to allow for attainment of steady-state conditions. KB-R7943 (50 mM, Alomone Labs, Israel) or SN-6 (10 mM, Tocris, UK), and BaCl 2 (1 mM) or tertiapin-Q (100 nM, Tocris, UK) were applied to block the Na + -Ca 2+ exchangers and K + channels, respectively.
To evaluate the effect of orexin on sensitivity and dynamic properties of LVN neurons, in current clamp recording, we injected a depolarizing ramp-like current ( Figure 5E1 ) in the absence or presence of orexin. This consisted of a 600 ms ramp (-150 pA to 150 pA, slop of 0.5 nA/s) followed by a long plateau of current (150 pA, 4400 ms) as in previous reports (Ris et al., 2001; Uno et al., 2003) . For in vivo recordings, all experimental procedures, including anesthesia, surgery, maintenance of the animals' physiological status, extracellular neuronal recording, data acquisition, and histology, have been described previously (Song et al., 2006; Zhu et al., 2006b ). Briefly, we initially anesthetized the rats (230-250 g) with urethane (800 mg/kg) plus a-chloralose (65 mg/kg) and supplemented when necessary. Unitary discharges of the neurons were conventionally recorded with a glass electrode filled with 1% solution of pontamine sky blue in 0.5 M sodium acetate (DC resistance 5-10 MU) and digitally recorded through an A/D interface (Power 1401, CED, UK). The dot raster displays and PSTHs of neuronal discharges were generated by the software Spike 2 (CED, UK).
Behavioral Tests
Male rats weighing 230-250 g were used in the behavioral tests. The animals were individually maintained in a thermoregulated (22 C-24 C) environment, and housed under a 12 hr light/dark cycle with lights on at 07:00 a.m. Standard rat chow and water were available ad libitum. The rats were anesthetized with sodium pentobarbital 40 mg/kg and mounted on a stereotaxic frame (1404, David Kopf Instruments, USA) under aseptic conditions. The lower ends of guide tubes (length 8 mm, o.d. 0.8 mm, i.d. 0.5 mm) were positioned 2.0 mm above the LVN (A À10.5 $ 10.8, L 2.2, and H 6.5, according to the rat brain atlas; Paxinos and Watson, 2007) . After the implantation, rats were caged individually and allowed to recover for at least 72 hr. During the behavioral testing sessions, two stainless-steel injection cannulae (length 10 mm, o.d. 0.5 mm, i.d. 0.3 mm) were inserted to protrude 2 mm beyond the tip of the guide tube and just above the LVN (to minimize lesioning the nuclei) for microinjection of orexin, SB334867, and vehicle (1 ml each side, lasting 2 min) using Hamilton syringes.
The animals were randomly divided into 4 groups: (1) sham operation, (2) microinjected with vehicle, (3) microinjected with orexin-A (dissolved in 0.9% NaCl), (4) microinjected with SB334867 (dissolved in 0.9% NaCl and 5% DMSO). The tail-hanging test was first performed following unilateral microinjection, whereas balance beam, negative geotaxis, accelerating rota-rod and open-field tests were conducted following bilateral microinjection. Each animal was trained daily for at least 10 trials for 3-5 consecutive days in order to achieve a stable performance on the accelerating rota-rod and balance beam. All tests started at the same time (10:00 a.m.) each day and each test was divided into four stages (before, 0 hr, 4 hr, and 24 hr after microinjections).
Tail-Hanging Test
The tail-hanging test was used to assess animals' posture. The rat was suspended by its tail with its forepaws on the ground. The total number of rotations in the direction contralateral to the microinjection site was recorded for 5 min.
Balance Beam Test
We assessed motor coordination and balance by measuring the ability of the animals to traverse a balance beam of 190 cm in length and a diameter of 2.5 cm. A plastic platform (7 cm 3 4 cm) was placed at one end of the rod as the start, and a black plastic box (15 cm 3 15 cm 3 8 cm) was at the other end of the rod to motivate the animal to cross the beam. The beam was placed horizontally or inclined with an elevation of 40 , above a cushion that served to protect animals that fell. The time taken to traverse the beam was recorded. To reduce stress and fatigue, the animals were allowed a 90 s rest between trials.
Negative Geotaxis Test
This test is considered as a diagnostic of vestibular function, reflex development, and motor skills (Altman and Sudarshan, 1975; Hermans et al., 1992) . Rats were placed on a 40 incline with their head pointing down the slope, and the time spent for a turn of 180 upward was recorded. The animals were allowed a 90 s rest between trials to reduce stress and fatigue. Accelerating Rota-Rod Test To assess motor performance during a major motor challenge we used a commercially available accelerating rota-rod (Ugo Basile, Italy). Animals were first habituated to low rotation (4 rpm) for 30 s, and then subjected to two trials of 4-40 rpm acceleration during 300, 180, or 60 s (acceleration was 0.12, 0.2, and 0.6 rpm/s, respectively), with a 3 min resting interval to reduce stress and fatigue. The time taken for the rat to fall from the rotating rod was recorded.
Open-Field Test
A square open field (50 cm 3 50 cm 3 40 cm) lit with a 60 W bulb above the field was used to assess general motor activity. The floor of the arena was divided into 25 identical squares of 10 cm length. After placing a rat at the center of the arena, locomotor activity expressed by the number of crossed squares and exploratory activity expressed by the number of rearings on hind feet were recorded during 5 min.
Histological Identification
On the last day of the behavioral tests, the animals were deeply anaesthetized with an overdose of sodium pentobarbital, and then two insulated stainless steel wires (o.d. 0.4 mm) with 0.2 mm exposed tip were inserted (10 mm) into the LVN under the guidance of guide tubes for depositing iron at the site of injection by passing DC current (10 mA, 20 s). The brain was then removed and fixed with 10% formaldehyde containing 1% potassium ferrocyanide. A week later, frozen serial coronal sections (80 mm in thickness) were prepared, and the blue dots indicating injection sites were identified according to the rat brain atlas (Paxinos and Watson, 2007) .
Statistical Analysis
All data are presented as mean ± SEM. The Student's t test, one-way and repeated-measures two-way analysis of variance (ANOVA), and NewmanKeuls post hoc testing was employed for statistical analysis.
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